Diversity and Inclusion in Clinical Trials Continues to be a Challenge
Despite the ongoing effort of the FDA and other regulatory agencies, as well as industry associations, sponsors, and research institutions, the U.S. continues to fall short in meeting diversity and inclusion goals for participation in clinical trials. According to a study by IQVIA, released Friday, clinical trial diversity dropped to its lowest level in a decade.
Diversity varied depending on the therapeutic area, with oncology representing the lowest participation of black and Hispanic patients.
The report did not suggest reasons nor offer possible solutions to this complex issue.
Here are two of the articles we have written on this important topic:
Diversity in Clinical Trials Starts with Diversifying Research Staff
https://www.brany.com/diversity-in-clinical-trials-starts-with-diversifying-research-staff
Could Diversity in Clinical Trials Become Mandatory?
https://www.brany.com/could-diversity-in-clinical-trials-become-mandatory/
